

## Candidates proposed for re-election at the company's annual general meeting on 10 October 2024

### Niels Thestrup (1962)

Member of the Board of Directors of ChemoMetec A/S since October 2021.

The Board of Directors proposes re-election of Niels Thestrup due to his special competencies in commercial law, including capital markets law, general corporate governance, economics and international business matters.

#### *Position*

Attorney-at-law (SC), Partner, Kønig Advokater I/S.

CEO of Thestrup Holding Advokatanpartsselskab, Thestrup Advokatanpartsselskab, N. Thestrup Holding ApS, Thestrup Ejendomme ApS and Ziegler Holding ApS

#### *Directorships*

Chairman of the Board of Directors of Co-Ros Fond, Nova5 Arkitekter a/s, Sani Membranes A/S, Løvbjerggård A/S, KG Holding, Søllerød ApS, Pnn Medical A/S, Pnn Medical US A/S, Pnn Memocore ApS and A/S Erik Thestrup.

Member of the Board of Directors of MedTech Invest A/S, Ejendomsselskabet Dr. Tværgade 5 A/S, Brancor Futures A/S and Brancor Securities A/S.

Niels Thestrup is recommended for election as a non-independent member of the Board of Directors in accordance with section 3.2.1 of the recommendations on Corporate Governance, as he is a partner in the law firm that provides legal advice to the company.

### Martin Glensbjerg (1959)

Member of the Board of Directors of ChemoMetec A/S since October 2013. He was also a member of the Board of Directors of ChemoMetec A/S in the period 2001-2010.

The Board of Directors proposes re-election of Martin Glensbjerg due to his special competencies in product development and project management as well as production and business development.

#### *Position*

Senior advisor at ChemoMetec A/S and co-founder of ChemoMetec A/S.

CEO of ChemoMetec Holding A/S and HMG Technology ApS.

#### *Directorships*

Board member of ChemoMetec Holding A/S, Sani Membranes A/S, Udviklingselskabet Hovedgaden 148 ApS and Byggeselskabet Danmark A/S.

Martin Glensbjerg is recommended for election as a non-independent member of the Board of Directors in accordance with section 3.2.1 of the recommendations on Corporate Governance, as he has been employed by the company as COO within the past five years.

### **Kristine Færch (1976)**

Member of the Board of Directors of ChemoMetec A/S since October 2020.

The Board of Directors proposes re-election of Kristine Færch due to her experience in research and development, broad biological expertise and in-depth knowledge of the work and challenges in the customer group that ChemoMetec is particularly targeting.

#### *Position*

Project Director, Data Science, Novo Nordisk A/S.

Kristine Færch is recommended for election as an independent member of the Board of Directors in accordance with section 3.2.1 of the recommendations on Corporate Governance.

### **Betina Hagerup (1961)**

Member of the Board of Directors of ChemoMetec A/S since October 2021.

The Board of Directors proposes re-election of Betina Hagerup due to her broad insight into both national and international business conditions, strategy and business development, digitalization and management.

#### *Position*

Board member.

#### *Directorships*

Chairman of Statens It-råd.

Member of the Board of Directors of the ATTA Foundation and the Centre for Cyberkompetencer.

Betina Hagerup is recommended for election as an independent member of the Board of Directors in accordance with section 3.2.1 of the recommendations on Corporate Governance.

### **Peter Reich (1962)**

Member of the Board of Directors of ChemoMetec A/S since October 2014.

The Board of Directors proposes re-election of Peter Reich due to his special competencies in strategy and business development, general corporate governance, specifically sales and marketing.

#### *Position*

Director and co-owner of the telecommunications company DSTNY A/S and CEO of Jore ApS, Soft Invest Holding ApS, Bulltrading ApS, IPV Holding ApS and Soft Holding ApS.

*Directorships*

Member of the Board of Directors of Leto Leasing P/S and BPM Micro ApS.

Peter Reich is recommended for election as an independent member of the Board of Directors in accordance with section 3.2.1 of the recommendations on Corporate Governance.